Skip to main
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 67%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris NV's positive outlook is driven by an increased global peak sales estimate for its drug deucrictibant, now projected to reach $1.65 billion by 2037. The clinical data showcases compelling patient outcomes, with 100% of participants achieving “well-controlled HAE” status and reporting significant improvements in health-related quality of life. Additionally, the favorable safety and efficacy profile, highlighted by robust single-dose durability and a significant market gap due to the absence of approved therapies, positions deucrictibant as a strong contender for capturing substantial market share if approved.

Bears say

Pharvaris NV faces significant challenges due to insufficient de-risking of bradykinin B2 receptor antagonism in chronic prophylaxis, which raises concerns about the efficacy and safety of its lead candidate, deucrictibant. The competitive landscape for hereditary angioedema (HAE) treatments is already crowded, with established therapies commanding market dominance, which could hinder Pharvaris's ability to gain traction. Additionally, the impending approval of multiple subcutaneous therapies in development may further dilute the potential market share for deucrictibant, severely impacting its commercial viability.

Pharvaris B.V. (PHVS) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 67% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 9 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.